REGENXBIO Inc.
RGNX
$9.01
$0.9011.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.20% | 469.79% | -4.50% | -16.31% | 11.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.20% | 469.79% | -4.50% | -16.31% | 11.60% |
| Cost of Revenue | -50.76% | -4.40% | 8.18% | -5.32% | -29.21% |
| Gross Profit | 37.85% | 174.68% | -7.74% | -2.31% | 132.83% |
| SG&A Expenses | 5.45% | 11.24% | -18.11% | -15.86% | -20.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 55.17% | 144.12% | 605.93% | -83.18% | 11.54% |
| Total Operating Expenses | 8.05% | -0.64% | -11.93% | -8.09% | -15.85% |
| Operating Income | -12.92% | 119.64% | 14.68% | 4.44% | 23.35% |
| Income Before Tax | -33.75% | 109.61% | 18.81% | 3.67% | 26.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.75% | 109.61% | 18.61% | 3.67% | 26.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.75% | 109.61% | 18.61% | 3.67% | 26.47% |
| EBIT | -12.92% | 119.64% | 14.68% | 4.44% | 23.35% |
| EBITDA | -14.21% | 127.93% | 15.26% | 4.08% | 24.30% |
| EPS Basic | -31.46% | 108.55% | 29.60% | 16.67% | 36.74% |
| Normalized Basic EPS | -31.46% | 108.84% | 25.39% | 16.67% | 36.74% |
| EPS Diluted | -31.46% | 108.55% | 29.60% | 16.79% | 36.92% |
| Normalized Diluted EPS | -31.46% | 108.83% | 25.39% | 16.67% | 36.74% |
| Average Basic Shares Outstanding | 1.74% | 12.31% | 15.61% | 15.60% | 16.24% |
| Average Diluted Shares Outstanding | 1.74% | 12.47% | 15.61% | 15.60% | 16.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |